Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Autor: du Bois, A, Kristensen, G, Ray-Coquard, I, Reuss, A, Pignata, S, Colombo, N, Denison, U, Vergote, I, Del Campo JM, Ottevanger, P, Heubner, M, Minarik, T, Sevin, E, de Gregorio, N, Bidziński, M, Pfisterer, J, Malander, S, Hilpert, F, Mirza, Mr, Scambia, G, Meier, W, Nicoletto, Mo, Bjørge, L, Lortholary, A, Sailer, Mo, Merger, M, Harter, P, AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium: Università degli Studi di Torino ITA, Ferrero, A, Et, Al

Publikováno v: Lancet Oncology, 17, 1, pp. 78-89
du Bois, A, Kristensen, G, Ray-Coquard, I, Reuss, A, Pignata, S, Colombo, N, Denison, U, Vergote, I, Del Campo, J M, Ottevanger, P, Heubner, M, Minarik, T, Sevin, E, de Gregorio, N, Bidziński, M, Pfisterer, J, Malander, S, Hilpert, F, Mirza, M R, Scambia, G, Meier, W, Nicoletto, M O, Bjørge, L, Lortholary, A, Sailer, M O, Merger, M, Harter, P & AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium 2016, ' Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12) : a randomised, double-blind, placebo-controlled phase 3 trial ', Lancet Oncology, vol. 17, no. 1, pp. 78-89 . https://doi.org/10.1016/S1470-2045(15)00366-6
Lancet Oncology, 17, 78-89

BACKGROUND: Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::978a413fe8167ddba627ac3f70a6cc68
https://doi.org/10.1016/s1470-2045(15)00366-6

Propensity score stratified MAP prior and posterior inference for incorporating information across multiple potentially heterogeneous data sources.

Autor: Zhu AY; Statistics and Decision Sciences, Janssen Research & Development, Johnson & Johnson, Raritan, New Jersey, USA., Roy D; Department of Biostatistics and Data Science, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA., Zhu Z; Department of Biostatistics and Data Science, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA., Sailer MO; Department of Biostatistics and Data Science, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Publikováno v: Journal of biopharmaceutical statistics [J Biopharm Stat] 2024 Mar; Vol. 34 (2), pp. 190-204. Date of Electronic Publication: 2023 Mar 07.

Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetes.

Autor: Fayette L; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.; Ecole des Ponts, UGE, Champs-sur-Marne, France., Sailer MO; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Perez-Pitarch A; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Publikováno v: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Oct; Vol. 12 (10), pp. 1386-1397. Date of Electronic Publication: 2023 Aug 30.

Probability of success for phase III after exploratory biomarker analysis in phase II.

Autor: Götte H; Merck KGaA, Darmstadt, Germany., Kirchner M; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany., Sailer MO; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.

Publikováno v: Pharmaceutical statistics [Pharm Stat] 2017 May; Vol. 16 (3), pp. 178-191. Date of Electronic Publication: 2017 Feb 23.